Related Experiment Videos
Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis
G Ristori1, F Laurenti, P Stacchini
1Department of Neurological Sciences, Università La Sapienza, Rome, Italy.
Journal of Neuroimmunology
|August 4, 1998
Summary
Peripheral inflammation markers like serum amyloid A protein (SAA) can be detected in multiple sclerosis (MS) patients. This study monitored SAA levels alongside brain imaging over three months.
Area of Science:
- Neuroimmunology
- Inflammatory diseases
Background:
- Multiple sclerosis (MS) exhibits central nervous system inflammation.
- Peripheral immune system activation markers are not consistently observed in MS.
Purpose of the Study:
- To investigate peripheral inflammation markers in relapsing-remitting MS.
- To correlate peripheral inflammation with central nervous system activity.
Main Methods:
- Serial monitoring of serum amyloid A protein (SAA) levels in peripheral blood.
- Parallel monitoring using gadolinium-enhanced magnetic resonance imaging (Gd-MRI) of the brain.
- Study duration of three months in MS patients.
Main Results:
- Elevated SAA levels indicate ongoing peripheral inflammation in MS patients.
- SAA serves as a detectable marker of systemic inflammatory activity.
- Peripheral inflammation signs can be identified in MS.
Conclusions:
- Serum amyloid A protein (SAA) is a viable marker for peripheral inflammation in multiple sclerosis.
- Monitoring SAA offers insights into systemic immune responses in MS.
- Findings suggest a link between peripheral inflammation and MS activity.